New Immunotherapy Options in Acute Lymphoblastic Leukemia: Implications for Nurses

Interact with your peers and experts while getting up to date on the latest immunotherapies for ALL in this dynamic 1-hour live meeting and then take home a pocket guide on key nursing considerations when caring for patients with ALL.


  • Brief Overview of ALL
  • New Immunotherapy Options in ALL
  • Antibody–Drug Conjugates and Bispecific T-Cell–Engager Antibody Therapy
  • CAR T-Cell Therapy
  • Minimal Residual Disease: Discussing the Meaning With Patients
  • Future Directions


Date / Time
Event Details


Mary Beth Rios, RN, CCRP

Director, Research Planning and Development
Department of Leukemia
University of Texas MD Anderson Cancer Center
Houston, Texas

Ma Welch, PA

Manager, Advanced Practice Providers
Department of Leukemia
University of Texas MD Anderson Cancer Center
Houston, Texas

Maura Abbott, PhD/ND/EdD

Assistant Professor of Nursing
Oncology Program Director
Nurse Practitioner
Department of Hematology/Oncology
Columbia University Medical Center
New York, New York

Sandra Allen-Bard, MSN

Leukemia Nurse Practitioner
Division of Leukemia
Department of Hematology/Oncology Medicine
Weill Cornell Medical College
Adult Leukemia Nurse Practitioner
Leukemia Service
Weill Cornell Medicine
New York, New York

Ilene Galinsky, NP

Senior Research Program Adult Leukemia Nurse Practitioner
Department of Leukemia
Dana-Farber Cancer Institute/Brigham and Women's Hospital
Boston, Massachusetts

Sandra E. Kurtin, PhD, ANP-C, AOCN

Hematology/Oncology Nurse Practitioner
Clinical Assistant Professor of Nursing
Clinical Assistant Professor of Medicine
Arizona Cancer Center
University of Arizona
Tucson, Arizona

Kristi Kay Orbaugh, RN

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, Indiana

Sara Tinsley, PhD/ND/EdD

Nurse Practitioner
Courtesy Assistant Professor
Department of Malignant Hematology
Moffitt Cancer Center
University of South Florida
Tampa, Florida


Nurse Lead
Hematologic Malignancies/Bone Marrow and Stem Cell Transplant
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Goal Statement
The goal of this activity is to improve oncology nurses’ ability to educate, partner in shared decision making with, and optimally care for patients with acute lymphoblastic leukemia.

Target Audience 
This program is intended for oncology nurses and other healthcare providers who care for patients with acute lymphoblastic leukemia.

Learning Objectives 

  • Explain to patients with ALL the limitations of standard treatment and potential benefit for novel immunotherapy options
  • Discuss the relative merits of single-agent immunotherapies vs antibody–drug conjugates vs CAR T-cell therapy for the treatment of ALL
  • Query patients for their preferences that may have a direct impact on choice of treatment for their ALL
  • Apply preventive as well as management strategies for treatment-related toxicities associated with novel therapeutics in ALL, including veno-occlusive disease and cytokine-release syndrome
  • Communicate effectively with patients to involve them in the prevention and management of treatment-related toxicities associated with novel therapeutics in ALL


Nursing Continuing Education

Joint Accreditation Statement
In support of improving patient care, Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1.0 contact hour.

A statement of credit will be made available immediately upon completion of the online evaluation.

Credit Designation 

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.